Many oncologic therapies can induce de novo hypertension or worsen pre-existing high blood pressure [120] through several mechanisms, including oxidative stress, endothelin-1 activity, prostaglandin imbalance, endothelial dysfunction, increased sympathetic activity, microvascular rarefaction, and reduced nitric oxide production [121,122]. The gene discussed is EDN1; the disease is hypertensive disorder.